Navigation Links
Myeloproliferative in Medical News

Late-breaking data to be presented at the American Society of Hematology Annual Meeting

... of a new tumor suppressor gene in patients with myeloproliferative disorders. "There is now additional evidence ... is a Novel Tumor Suppressor Gene Inactivated in myeloproliferative Neoplasms: Identification of a Pre-JAK2 V617F ... which is altered in 14 percent of patients with myeloproliferative disorders, providing scientists with a greater ...

Cytopia Lodges IND for JAK2 Inhibitor CYT387

... is implicated in a variety of haematological conditions known as the myeloproliferative disorders (MPDs). This suite of conditions includes myelofibrosis, ... with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders and cancer, expected to enter Phase I clinical studies in 2009. ...

Scientists Identify Key Gene That Protects Against Leukemia

... led by 6 to 12 months post-transplantation to the development of a myeloproliferative disease, which can evolve to leukemia. The finding indicated that the ... lineage than the control group, indicating constant regeneration of a myeloproliferative disease from JunB-deficient HSCs that persisted after treatment. When ...

S*BIO Announces Collaboration with Onyx for JAK2 Inhibitors in the North American and European Markets

... of SB1518 will initially focus on the treatment of myelofibrosis and other myeloproliferative diseases. JAK2 inhibitors are implicated across a broad range of ... V617F mutation. The V617F mutation is found in high frequencies in various myeloproliferative disorders such as idiopathic myelofibrosis. SB1518 might also provide an ...

Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO

... activation of JAK2 stimulates blood cell production. Genetic mutations in the JAK2 enzyme result in up-regulated activity and are implicated in myeloproliferative diseases (MPD), conditions characterized by an overproduction of blood cells in the bone marrow. The MPD conditions where JAK2 mutations are most ...

Experimental Drug Fights Bone Marrow Cancers

... TUESDAY, Dec. 9 (HealthDay News) -- An experimental drug called CYT387 blocks an enzyme that causes bone marrow cancers called myeloproliferative disorders (MPDs), according to U.S. researchers who conducted tests in mice and human cells. The findings were to be presented Tuesday at the ...

Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry

... nomination candidates and clinical development drugs for potential treatment for cancer, thrombosis, ocular disease, inflammation, edema and myeloproliferative disorders. As the Vice President of Medicinal Chemistry Dr. Soll will help the company to expand and strengthen its medicinal chemistry services ...

Increased cancer risk following the use of radioactive Radium-224 in the therapy

... "It is rather unlikely that impurities present in the radium preparations used before 1950 are responsible for the elevated appearance of myeloproliferative diseases in the exposed group observed here," commented Dr. Roland R. Wick. "In addition, the increased incidence of leukaemia is in line with ...

Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research

... class cancer therapy. In addition, S*Bio received orphan drug approval from FDA to conduct clinical trials for a drug that is designed to treat myeloproliferative disorders (MPD), a disease which if untreated can lead to cardiovascular diseases and leukemia. 3. The Institute of Bioengineering and ...

Stem cell research leads to potential new therapy for rare blood disorder

... A unique partnership between industry and academia has led to human clinical trials of a new drug for a rare class of blood diseases called myeloproliferative disorders (MPD), which are all driven by the same genetic mutation and can evolve into leukemia. In just one year, collaborative discoveries by stem ...
Myeloproliferative in Medical Technology

Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting

... of a new tumor suppressor gene in patients with myeloproliferative disorders. "There is now additional ... Novel Tumor Suppressor Gene Inact i vated in myeloproliferative Neoplasms: Identification of a Pre- J AK2 ... which is altered in 14 percent of patients with myeloproliferative disorders, providing scientists with a greater ...

Cytopia Scientific Presentations on JAK2 Inhibitor Program

... a lecture entitled Targeted JAK2 Inhibitors for myeloproliferative Disorders at the annual meeting of the ... will present his lecture JAK2 Inhibitors for myeloproliferative Disorders at the 'Drug Discovery on Target' ... as a potent and selective compound for treating myeloproliferative disorders (MPDs). Subject to regulatory ...

Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders

... for formal preclinical development to treat myeloproliferative disorders (MPDs). This follows extensive ... an in-vivo model of myeloproliferative disease. myeloproliferative disorders are a group of diseases ... efficacy in a well-validated in-vivo model of myeloproliferative disorders in studies in the laboratory ...

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

... lestaurtinib inhibits FLT3 activity and induces cell death (apoptosis). In myeloproliferative disorders, mutations in JAK2 may play a role in allowing large numbers of ... this activity, lestaurtinib is in ongoing studies for the treatment of myeloproliferative disorders. About Cephalon Oncology Cephalon, a leading ...

TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients

... results from a multi-center, US-based clinical trial of TG101348 in myeloproliferative disease patients has been scheduled at the 2008 American Society of ... Dr. Animesh Pardanani, Mayo Clinic Session Name: myeloproliferative Disorders-Experimental Therapeutics Session Date: Sunday, ...

TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients

... an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases. (Logo: ... (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce ...

TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH

... A JAK2 Selective Small Molecule Inhibitor, in the Presence of myeloproliferative Disorder-Associated JAK2V617F, MPLW515K, or Exon 12 Mutations -- ... (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce to reduce ...

Mutant Genes in High-Risk Childhood Leukemias Identified

... clinical trials of inhibitory drugs to treat such cancers. "JAK-inhibiting drugs are now moving into clinical trials for treatment of such adult myeloproliferative diseases as polycthemia vera, essential thrombocytosis and primary myelofibrosis," Downing said. "We expect that there will soon be initial clinical ...

Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays

... development, non-exclusive rights, for the US territory, to offer a complete range of assays for the molecular classification and the screening of myeloproliferative Neoplasms (MPN), a group of leukaemia's caused by JAK2 gene variations that affects more than 100,000 people in the US. Additional terms were not ...

Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997

... to build on its range of JAK inhibitors and kinase expertise. CYT387, a novel, orally administered JAK2 inhibitor focused on the treatment of myeloproliferative disorders is expected to enter Phase I clinical studies in 2009. ...
Myeloproliferative in Medical Definition

Hematopathology

... . Diseases of Hematopoietic Cells The major disease of hematopoietic cells fall into several categories, which include chronic myeloproliferative disease , myelodysplastic syndromes , leukemias , lymphomas , plasma cell neoplasms , and histiocytic and mast cell neoplasms. ...
Myeloproliferative in Medical Dictionary

Myeloproliferative Disorders

... myeloproliferative disorders : Malignant disease s of certain bone ... platelet s (crucial to blood clotting). myeloproliferative disorders are a group of disease s in which the ... or platelet s. There are 6 types of chronic myeloproliferative disorders . Expanded indication: treatment ...

Polycythemia

... caused by sickle cell disease , may cause blood clots to form. The myeloproliferative disorders include myelophthisic anemia , erythroblastic leukemia , ... indication: treatment of patients with thrombocythemia, secondary to myeloproliferative disorders such as polycythemia vera (PV) and chronic myelogenous ...

Polycythemia vera

... chronic , progressive disease , most common in middle-aged men. The myeloproliferative disorders include myelophthisic anemia , erythroblastic leukemia , ... indication: treatment of patients with thrombocythemia, secondary to myeloproliferative disorders such as polycythemia vera (PV) and chronic myelogenous ...

Osler

... me about hereditary hemorrhagic telangiectasia ? Diane/ Canada ... : Cryptogenic Polycythemia , Erythremia, Erythrocytosis Megalosplenica, myeloproliferative Disorder, Osler 's Disease , Polycythemia Rubra Vera, Polycythemia with Chronic Cyanosis - Myelopathic Polycythemia , Primary ...

Platelet count

... bleeding . Adult treatment usually begins with oral prednisone. Expanded indication: treatment of patients with thrombocythemia, secondary to myeloproliferative disorders such as polycythemia vera (PV) and chronic myelogenous leukemia ( CML ), to reduce the elevated platelet count and the risk of ...
Myeloproliferative in Biological News

La Jolla Institute discovers novel tumor suppressor

... as a tumor suppressor that may be important in myeloproliferative diseases and some types of lymphoma and leukemia. myeloproliferative diseases are a group of disorders characterized ... further, choosing to focus specifically on myeloproliferative disease because almost all of the mice with a ...

Scientists identify key gene that protects against leukemia

... led by 6 to 12 months post-transplantation to the development of a myeloproliferative disease, which can evolve to leukemia. The finding indicated that the ... lineage than the control group, indicating constant regeneration of a myeloproliferative disease from JunB-deficient HSCs that persisted after treatment. When ...

Genetic abnormality may increase risk of blood disorders

... inherited DNA sequence changes that frequently occur in patients with myeloproliferative neoplasms, in which several types of blood cells are excessively produced ... by the DNA sequence. More than half of patients afflicted with myeloproliferative neoplasms which affect an estimated 140,000 people in the US carry the ...

AACR hosts Molecular Diagnostics in Cancer Therapeutic Development Meeting

... Genetic markers for glioblastoma survival New data on nanotechnology as a cost effective diagnostic method More accurate tools for diagnosing myeloproliferative neoplasia Late-breaking data on multispectral imaging and its utility How the Epstein Barr virus predicts outcome in nasopharyngeal carcinoma ...
Myeloproliferative in Biological Technology

Cytopia Letter to Progen Shareholders

... with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009. ... with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009. ...

Presentation on Cytopia's JAK2 Inhibitor Program in Myeloproliferative Disorders

... University and will overview the study of CYT387 in an in- vivo model of myeloproliferative disorders. Full presentation details: Effects of ... with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in early 2009. ...

Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting

... 3127 Title: AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F myeloproliferative Disease Models. Session Name: myeloproliferative Syndromes: Therapy Session Date: Monday, December 10, 2007 Presentation ...

Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO

... is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in mid 2009. Website: www.cytopia.com.au ...

Cytopia Presentation on VDA CYT997 at AACR Conference

... is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009. Website: www.cytopia.com.au ...

Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference

... to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009. Website: www.cytopia.com.au ...

Progen Concedes Shareholder Requisitioned Meeting

... is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009. ...

Cytopia and Other Progen Shareholders Maintain Call for Meeting

... to build on its range of JAK inhibitors and kinase expertise. CYT387, a novel, orally administered JAK2 inhibitor focused on the treatment of myeloproliferative disorders is expected to enter Phase I clinical studies in 2009. ...

Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders

... is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in early 2009. Website: www.cytopia.com.au Director Candidate Biographies Mr. ...

In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring of Leukemia

... a significant role in the monitoring of this disease. - MutaScreen MPL, a research kit for the detection of MPL mutations in JAK2 negative myeloproliferative neoplams (MPN), is a significant addition to the MPD family of products that Ipsogen offers. These 3 new tests exemplify Ipsogen's ...
Myeloproliferative in Biological Dictionary

Nucleolar organizer

... Organizer ' How to ... nucleolar organizer . Type: Term. Definitions: ... Nucleolar organizer regions of megakaryocytes in chronic myeloproliferative disorders. ... Alteration of argyrophilic nucleolar organizer region associated (Ag ... In recent years, nucleolar organizer region (NOR) ...

Basophils

... UFP ... What is Basophils ? Meaning of Basophils medical term. What does Basophils mean? ... The relative number of basophils increases in myeloproliferative diseases and ... 1.3.1 Mast cells and basophils ... Basophils are the smallest circulating granulocytes with relatively the least known ...
Other Contents
(Date:4/14/2014)... Porter Graham Child Development Institute have released their ... to prepare four-year-olds for success in kindergarten. According ... show significant gains across all areas of learning. ... greater rate during their participation in NC Pre-K ... scientist Ellen Peisner-Feinberg, who leads the FPG team ...
(Date:4/14/2014)... children with uncomplicated acute appendicitis is a reasonable alternative ... missed school days, according to a pilot study. The ... and published online April 12 in the Journal ... first prospective study on nonoperative management of acute appendicitis ... Researchers enrolled 77 patients age 7 to 17 who ...
(Date:4/14/2014)... shows that domestic abuse is closely linked to ... stress disorder (PTSD), in mothers. The research also ... with specific mental health problems. The work was ... Simon Fraser University and the University of British ... how intimate partner abuse physical, psychological and ...
(Date:4/13/2014)... program for adolescent girls in Kenyan slums sharply ... who live in an environment where women have ... new study shows. , The findings, by researchers ... Packard Children,s Hospital Stanford and the nongovernmental organization ... in combating an appallingly common hazard among girls ...
(Date:4/11/2014)... a severe disease for which there is still no ... what happens in the brain of a schizophrenic person, ... proteins in the brains of rats that have been ... new and better medicines. , Seven per cent of ... have tried for centuries to understand the disease, they ...
Breaking Medicine News(10 mins):Health News:Study gives high marks to NC Pre-K program 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Study links domestic abuse to mental health problems in new mothers 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4Health News:Protein researches closing in on the mystery of schizophrenia 2Health News:Protein researches closing in on the mystery of schizophrenia 3
(Date:4/15/2014)... Center in Greenbelt, Md., is home to hundreds ... At Goddard, some of the most cutting-edge Earth ... of that cutting-edge innovation has earned a Goddard ... Society for Anthropology and Geography awards the Vega ... has shown excellence in the fields of physical ...
(Date:4/15/2014)... study of nearly 1,000 mother-child pairs, researchers from ... prenatal exposure to selective serotonin reuptake inhibitors (SSRIs), ... other disorders, was associated with autism spectrum disorder ... study, published in the online edition of ... ASD and DD cases, and population-based controls, where ...
(Date:4/15/2014)... University of Missouri researchers have previously shown that a ... exercise exists. In a new study, Frank Booth, a ... found a potential link between the genetic pre-disposition for ... which mental maturation occurs. , For his study, Booth ... activity or extreme laziness. Booth then put the rats ...
Breaking Biology News(10 mins):Goddard scientist receives Vega Medal from King of Sweden 2Study: SSRI use during pregnancy associated with autism and developmental delays in boys 2Genetic pre-disposition toward exercise and mental development may be linked 2
Other TagsOther Tags